{"schema_version":"1.0","type":"article","title":"這家台灣Biotech正在打造人體內奈米火箭","url":"https://drugnews.com.tw/articles/2026-08-13-intelligene-rna-delivery-nanorocket.html","markdown_url":"https://drugnews.com.tw/articles/2026-08-13-intelligene-rna-delivery-nanorocket.md","lang":"zh-Hant","date":"2026-08-13","publish_at":"2026-08-13T10:30:00+08:00","updated_at":"2026-08-13","category":"商業分析系列","topic":"商業分析系列","tags":["智新生物","Intelligene","RNA 遞送","小核酸藥物","siRNA","ASO","EV 外泌體","LNP","肝外遞送","台灣生技"],"summary":"小核酸藥物的競爭正從 RNA 序列設計走向肝外遞送；智新生技以 EV 與 LNP 平台切入肺部與呼吸道，挑戰小核酸下半場最值錢的問題：能否真正抵達病灶。","key_points":[],"facts":[],"sections":["01｜小核酸已經從故事，變成賣得動的藥","02｜肝臟是第一個軌道，但不是最後一站","03｜市場正在用「器官難度」重新定價 RNA 平台","04｜智新打造人體內的奈米火箭","05｜EV 外泌體：真正的門檻在製程，不在想像","06｜澳洲布局：把台灣平台接上國際臨床航道","07｜接下來，市場會看的是升空數據","結語｜小核酸下半場，真正的價值在抵達","參考資料","免責聲明"],"references":[{"title":"[Alnylam, Inceptive sign up to $2 billion AI drug discovery deal","source":"Reuters]","date":"","url":"https://www.reuters.com/legal/litigation/alnylam-inceptive-sign-up-2-billion-ai-drug-discovery-deal-2026-06-03/"},{"title":"[The Leading RNAi Therapeutics Company","source":"Alnylam]","date":"","url":"https://www.alnylam.com/"},{"title":"[Bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B","source":"GSK]","date":"","url":"https://www.gsk.com/en-gb/media/press-releases/bepirovirsen-achieves-unprecedented-functional-cure-rates-with-potential-to-redefine-treatment-for-chronic-hepatitis-b/"},{"title":"[核心技術 - Intelligene Inc.","source":"Innovate the cures of tomorrow.]","date":"","url":"https://www.intelli-gene.com/en/research"},{"title":"[媒體發表 - Intelligene Inc.","source":"Innovate the cures of tomorrow.]","date":"","url":"https://www.intelli-gene.com/en/news"}],"images":[{"alt":"圖1｜小核酸藥物的上半場是序列設計，下半場是遞送能否抵達病灶","url":"https://drugnews.com.tw/assets/articles/intelligene-rna-delivery-nanorocket/figure-01.png"},{"alt":"圖2｜小核酸藥物從商業化產品、慢性 B 肝功能性治癒訊號到肝外遞送新戰場","url":"https://drugnews.com.tw/assets/articles/intelligene-rna-delivery-nanorocket/figure-02.png"},{"alt":"圖3｜肝臟之外的器官遞送難度，正在重新定價 RNA 平台公司","url":"https://drugnews.com.tw/assets/articles/intelligene-rna-delivery-nanorocket/figure-03.png"},{"alt":"圖4｜智新生技以肺部與呼吸道為起點，打造 EV 與 LNP RNA 遞送平台","url":"https://drugnews.com.tw/assets/articles/intelligene-rna-delivery-nanorocket/figure-04.png"},{"alt":"圖5｜智新生技的下一階段估值變數，包括臨床前資料、IND、Phase 1、CMC 與國際合作","url":"https://drugnews.com.tw/assets/articles/intelligene-rna-delivery-nanorocket/figure-05.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/intelligene-rna-delivery-nanorocket/cover-1400.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-08-13）。這家台灣Biotech正在打造人體內奈米火箭。https://drugnews.com.tw/articles/2026-08-13-intelligene-rna-delivery-nanorocket.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-08-13-intelligene-rna-delivery-nanorocket-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}